Novo Nordisk Faces a Fork in the Road: Oral Wegovy Momentum Meets CagriSema’s FDA Gamble
Published on 07/22/2026 at 03:51 | Redaktion boerse-global.de
Novo Nordisk’s stock has been treading water, closing near €43.30 on Tuesday with barely a flicker of movement. The Danish drugmaker’s shares have clawed back 43% from their 52-week low, yet they remain roughly 29% below the all-time peak hit in July 2025. That stark gap captures the tension running through the company today: a promising oral Wegovy rollout is gaining traction, but the bigger prize — and the bigger risk — hinges on a pivotal FDA decision for CagriSema due by year-end.
Citi turns more bullish on the pill, but holds the line on rating
Citi analyst Graham Parry has lifted his price target on Novo Nordisk to 330 Danish kroner from 290, while keeping a “Neutral” rating. The upgrade is driven by an updated financial model that bumps up revenue and operating profit forecasts for 2026 by 4% to 5%, with earnings-per-share estimates for 2027 through 2030 rising by roughly 7%. Currency effects play a part, but the real catalyst is stronger-than-expected demand for the oral version of Wegovy in the second quarter.
The new target is based on 16 times projected 2027 earnings, up from 15 times previously — a direct nod to growing confidence in the pill franchise. For the upcoming quarterly report on August 5, Citi expects adjusted operating profit of 27.2 billion Danish kroner, a 9% decline at constant exchange rates, and revenue of 72.7 billion kroner, down 1%. Both figures exclude US rebate effects from the 340B program. The oral Wegovy pill is expected to contribute 4 billion kroner (roughly $630 million) to offset ongoing pricing pressure in the diabetes and obesity businesses.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Despite the higher target, Citi’s neutral stance remains unchanged. The broader analyst community shares that caution: 18 of 26 analysts covering the stock rate it a hold or sell. Deutsche Bank’s Emmanuel Papadakis recently reaffirmed a hold rating with a 290-kroner target, well below Citi’s new figure.
CagriSema: The make-or-break catalyst
While the Wegovy pill story is encouraging, the real inflection point for Novo Nordisk lies with CagriSema, its next-generation obesity therapy. The company submitted CagriSema to the FDA in December 2025, based on the REDEFINE 1 and REDEFINE 2 studies, and expects a decision by the end of 2026. Additional data from REDEFINE 11, designed to explore the drug’s full weight-loss potential, won’t arrive until the first half of 2027. A separate Phase 3 study testing a higher dose is set to begin in the second half of 2026.
The central question is whether CagriSema can compete head-to-head with Eli Lilly’s dominant tirzepatide franchise. In the REDEFINE 4 study, patients on CagriSema 2.4 mg achieved a 23.0% weight loss after 84 weeks, versus 25.5% for tirzepatide 15 mg. That gap explains why the FDA verdict carries so much weight — and why Novo is racing to close the efficacy gap with a higher-dose study.
Novo is also exploring a regulatory path for CagriSema in type 2 diabetes, following results from REIMAGINE 1 and REDEFINE 3, but no formal submission strategy has been announced yet.
Bull case: Portfolio breadth and oral leadership
Optimists point to Novo’s expanding pipeline beyond CagriSema. The oral Wegovy tablet has now secured its fifth global approval and is set to launch in additional countries during the second half of 2026, giving Novo a first-mover advantage in oral obesity therapies over Lilly’s still-unapproved European contender. Management has already raised expectations for GLP-1 product sales, betting on continued global market growth to drive volume expansion.
Technically, the stock is showing recovery momentum. It trades 7.8% above its 50-day moving average of €40.17 and sits above its 200-day average of €40.44. The relative strength index of roughly 58 suggests upward momentum without being overbought, leaving room for further gains if CagriSema news turns positive.
Bear case: Pricing pressure and an unproven edge
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The risks are equally concrete. Novo’s own guidance flags structural headwinds: lower realized prices from the US “Most Favoured Nations” agreement, loss of market exclusivity for semaglutide in some international markets, and reduced Medicaid coverage for obesity drugs. Intensifying competition in the US adds another layer of pressure.
The efficacy gap with tirzepatide remains unresolved. REDEFINE 11 data that could close that gap won’t arrive until early 2027 — a long wait during which Lilly can keep building market share. The stock’s 22% decline over the past 12 months and its 29% distance from the 52-week high suggest considerable skepticism is already priced in.
What to watch next
The August 5 earnings report will provide the first concrete update on oral Wegovy’s international rollout and whether its momentum can offset the pricing drag in Novo’s core business. But the bigger test comes later this year: the FDA’s decision on CagriSema, along with the start of the higher-dose study, will determine whether Novo can reclaim its growth narrative — or whether the bears have been right all along.
Ad
Novo Nordisk Stock: New Analysis - 22 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
